07 January 2025
07 January 2025
The acquisition is expected to be finalised by the end of this year’s first quarter.
The investment will facilitate the company’s continued expansion in various healthcare environments.
NanoVibronix previously said data from the study would support a permanent FDA clearance.
MmHg’s platform software enables healthcare providers to align patient data with clinical best practices.
ARS Pharma has established licensing partnerships for the spray in China, Japan, Australia and New Zealand.
Castle Biosciences' TissueCypher test predicts a patient’s risk of progression from Barrett’s oesophagus to oesophageal cancer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
